UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Astria Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

04635X102

(CUSIP Number)

December 31, 2022

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)

[x] Rule 13d-1(c)

[] Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

1		porting Persons.
	I.R.S. Identif	ication Nos. of above persons (entities only)
	Commonant C	lobal Healthcare Master Fund, LP
	Connorant G	100al Healthcare Master Fund, LP
2		ppropriate Box if a Member of a Group (See Instructions)
	(a) [
	(b) [2	
3	SEC Use Onl	
4	Citizenship o	r Place of Organization.
	Cayman Islaı	nds
	-	5 Sole Voting Power
		0 shares
		6 Shared Voting Power
		o Shared voting i ower
	Number	1,650,000 shares
	of Shares Beneficially	
	Owned by	Refer to Item 4 below.
	Each	7 Sole Dispositive Power
	Reporting	0 shares
	Person With	8 Shared Dispositive Power
		o shared Dispositive Fower
		1,650,000 shares
		Refer to Item 4 below.
9	Aggregate A	mount Beneficially Owned by Each Reporting Person
	1,650,000 sha	ares
10	Refer to Item	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
10	[] N/A	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11		ass Represented by Amount in Row (9)*
	6.30%	
	0.5070	
	Refer to Item	
12	Type of Repo	orting Person (See Instructions)
	PN (Partners)	hip)

1		porting Persons.
	I.R.S. Identif	ication Nos. of above persons (entities only)
	Cormorant G	ilobal Healthcare GP, LLC
2	Check the Ap	opropriate Box if a Member of a Group (See Instructions)
	(a) [
		X]
3	SEC Use Onl	
4	Citizenship o	or Place of Organization.
	Delaware	
		5 Sole Voting Power
		0 shares
		6 Shared Voting Power
	Normhan	
	Number of Shares	1,650,000 shares
	Beneficially	
	Owned by	Refer to Item 4 below.
	Each	7 Sole Dispositive Power
	Reporting	0 shares
	Person With	8 Shared Dispositive Power
		1,650,000 shares
		Refer to Item 4 below.
9	Aggregate A	mount Beneficially Owned by Each Reporting Person
	1,650,000 sh	ares
	Refer to Item	a 4 below.
10	Check if the	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
	[] N/A	
11	Percent of Cl	ass Represented by Amount in Row (9)*
	6.30%	
	Refer to Item	4 below.
12		orting Person (See Instructions)
	OO (Limited	Liability Company)

1		porting Persons. ication Nos. of above persons (entities only)
	I.K.S. Identii	reation Nos. of above persons (entities only)
	Cormorant A	asset Management, LP
2		ppropriate Box if a Member of a Group (See Instructions)
	(a) [
3	(b) [SEC Use On	x] v
4		or Place of Organization.
	Delaware	
		5 Sole Voting Power
		0 shares
		6 Shared Voting Power
	Number	
	of Shares	1,650,000 shares
	Beneficially Owned by	Refer to Item 4 below.
	Each	7 Sole Dispositive Power
	Reporting	0 shares
	Person With	8 Shared Dispositive Power
		1,650,000 shares
		1,050,000 shares
		Refer to Item 4 below.
9	Aggregate A	mount Beneficially Owned by Each Reporting Person
	1,650,000 sh	ares
	Refer to Item	a 4 below.
10	Check if the	Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11	[] N/A Percent of C	lass Represented by Amount in Row (9)*
11	I creent of ch	tass represented by Amount in Row (7)
	6.30%	
	Refer to Item	
12	Type of Repo	orting Person (See Instructions)
	PN (Partners	hip)

1	Names of Re	porting Persons.
		ication Nos. of above persons (entities only)
	Bihua Chen	
	Dinua Chen	
2	Check the Ar	ppropriate Box if a Member of a Group (See Instructions)
-	(a) [
	(b) [2	
3	SEC Use Onl	
4		r Place of Organization.
4	Citizenship o	
	United States	
	Onice Suites	5 Sole Voting Power
		5 Sole Vollig I ower
		0 shares
		6 Shared Voting Power
		o Shared volling Power
	Number	1 (50 000 shares
	of Shares	1,650,000 shares
	Beneficially	
	Owned by	Refer to Item 4 below.
	Each	7 Sole Dispositive Power
	Reporting	
	Person With	0 shares
		8 Shared Dispositive Power
		1,650,000 shares
		Refer to Item 4 below.
9	Aggregate A	mount Beneficially Owned by Each Reporting Person
	1,650,000 sha	ares
	Refer to Item	
10		Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
	[] N/A	
11	Percent of Cl	ass Represented by Amount in Row (9)*
	(200)	
	6.30%	
	Refer to Item	
12	Type of Repo	orting Person (See Instructions)
	BT (T 1 1 1 1	
	IN (Individua	u)

Item 1.

(a)	Name of Issuer
	Astria Therapeutics, Inc.
(b)	Address of Issuer's Principal Executive Offices
	75 State Street, Suite 1400, Boston, MA 02109
Item 2.	
(a)	Name of Person Filing
	Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Asset Management, LP Bihua Chen
(b)	Address of Principal Business Office or, if none, Residence
	200 Clarendon Street, 52nd Floor Boston, MA 02116
(c)	Citizenship
	Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware Cormorant Asset Management, LP - Delaware Bihua Chen - United States
(d)	Title of Class of Securities
	Common Stock
(e)	CUSIP Number 04635X102

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	[]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
(b)	[]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	[]	Insurance Company as defined in Section 3(a)(19) of the Act
(d)	[]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)	[]	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	[]	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	[]	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	[]	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	[]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company
		Act of 1940 (15 U.S.C. 80a-3);
(j)	[]	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k)	[]	Group, in accordance with §240.13d-1(b)(1)(ii)(K).

Item 4. Ownership***

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned***

The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

(b) Percent of Class

The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote

- (ii) shared power to vote or to direct the vote
- (iii) sole power to dispose or to direct the disposition of
- (iv) shared power to dispose or to direct the disposition of

The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

*** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.

The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in the Issuer's prospectus dated December 15, 2022, as filed with the Securities and Exchange Commission on December 15, 2022, that that there would be 26,193,373 shares of common stock of the Issuer outstanding after the public offering to which the Prospectus related if the underwriters thereof exercised their overallotment option in full, and (ii) a statement in a press release from the Issuer dated December 19, 2022, that the closing of such offering had occurred and that such overallotment option was exercised in full.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of Group

Not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits Exhibit

99.1 Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on September 2, 2022.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

February 14, 2023

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP By: Cormorant Global Healthcare GP, LLC its General Partner

By: <u>/s/ Bihua Chen</u> Bihua Chen, Managing Member

CORMORANT GLOBAL HEALTHCARE GP, LLC

By: <u>/s/ Bihua Chen</u> Bihua Chen, Managing Member

CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC its General Partner

By: <u>/s/ Bihua Chen</u> Bihua Chen, Managing Member

<u>/s/ Bihua Chen</u> Bihua Chen